FDA recalls 90,000 bottles of children's ibuprofen over contamination fears

The US Food and Drug Administration (FDA) has recalled nearly 90,000 bottles of Children's Ibuprofen Oral Suspension. The move follows reports of black particles and other contaminants in the berry-flavoured medication, which is meant for children aged 2 to 11. Manufactured in India by Strides Pharma Inc., the product was pulled from shelves as a precautionary step.

The recall began after customers complained about finding a gel-like substance and black particles in the liquid medicine. Strides Pharma Inc., the Indian manufacturer, started the process, though neither the company nor Taro Pharmaceuticals—the brand listed on the product—has publicly commented on the issue.

The FDA has classified the recall as low risk, stating that serious health consequences are unlikely. However, the agency has been tightening oversight of overseas drug production. Recent inspections in India, part of a pilot programme alongside China, identified quality control concerns. These checks fall under broader reforms, including the FDA's 'Simple Reform' initiative, which shifts back to generalist inspectors rather than specialists. The recalled ibuprofen suspension is widely used to reduce fever and pain in young children. While the FDA emphasises the low probability of harm, the incident highlights the importance of strict quality checks, especially for medicines designed for vulnerable age groups.

The recall removes nearly 90,000 bottles from circulation, with no reports yet of adverse health effects. The FDA continues to monitor drug safety through inspections and policy reforms. Manufacturers and regulators face ongoing pressure to ensure medications, particularly those for children, meet strict quality standards.